China Reaches ’Lower-Moderate’ TB Incidence for First Time
00:00/00:00
Listen to this article
1x
Subscribe now
Listen to the full version
Listen to the full version
China is now classified as having a “lower-moderate” incidence of tuberculosis, the World Health Organization (WHO) said, marking the first time it has reached this category.
The country’s estimated number of new TB cases fell to 696,000 in 2024, a 6.1% drop from the previous year, with an incidence rate of 49 per 100,000 people, down 5.8%, according to the WHO’s Global Tuberculosis Report 2025 released Wednesday. The progress moved China from the third- to the fourth-highest country in terms of new cases, placing it in the “lower-moderate” incidence category.
You've accessed an article available only to subscribers
VIEW OPTIONS
Unlock exclusive discounts with a Caixin group subscription — ideal for teams and organizations.
Subscribe to both Caixin Global and The Wall Street Journal — for the price of one.
- RELATED
Share this article
Open WeChat and scan the QR code
- DIGEST HUB
Digest Hub
Back
Explore the story in 30 seconds
- China’s TB incidence dropped to 49 per 100,000 in 2024, moving it to a “lower-moderate” category, with new cases falling 6.1% to 696,000.
- Globally in 2024, 10.7 million contracted TB and 1.23 million died; progress lags behind the WHO 2025 targets.
- TB funding in 2024 was $5.9 billion—just 27% of the target—with further cuts likely to worsen outcomes.
AI generated, for reference only
What Happened When
- 2024：
- China's estimated number of new TB cases fell to 696,000, a 6.1% drop from the previous year with an incidence rate of 49 per 100,000 people (down 5.8%).
- 2024：
- Global spending on TB prevention, diagnosis, and treatment reached $5.9 billion, just 27% of the annual target for 2027.
- By 2024：
- Globally, an estimated 10.7 million people contracted TB and 1.23 million died from the disease in the previous year.
- As of 2024：
- Globally, TB incidence and death rates fell by only 12% and 29% respectively from 2015 levels, far short of 'End TB Strategy' goals for 2025.
- December 2024：
- China approved the new drug pretomanid for treating highly drug-resistant TB.
- December 2024：
- China released a national TB prevention and control plan for 2024–2030.
- Starting in 2025：
- International donor funding for TB prevention, diagnosis, and treatment is expected to be cut.
- November 13, 2025：
- WHO released the Global Tuberculosis Report 2025, announcing China's new classification as 'lower-moderate' TB incidence.
AI generated, for reference only
- PODCAST
- MOST POPULAR
Sign in with Google
Sign in with Facebook
Sign in with 财新